These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37770315)

  • 1. Covalent fragment approaches targeting non-cysteine residues.
    Csorba N; Ábrányi-Balogh P; Keserű GM
    Trends Pharmacol Sci; 2023 Nov; 44(11):802-816. PubMed ID: 37770315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covalent drug discovery using sulfur(VI) fluoride exchange warheads.
    Huang H; Jones LH
    Expert Opin Drug Discov; 2023 Jul; 18(7):725-735. PubMed ID: 37243622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
    Gehringer M; Laufer SA
    J Med Chem; 2019 Jun; 62(12):5673-5724. PubMed ID: 30565923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophilic warheads in covalent drug discovery: an overview.
    Péczka N; Orgován Z; Ábrányi-Balogh P; Keserű GM
    Expert Opin Drug Discov; 2022 Apr; 17(4):413-422. PubMed ID: 35129005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A road map for prioritizing warheads for cysteine targeting covalent inhibitors.
    Ábrányi-Balogh P; Petri L; Imre T; Szijj P; Scarpino A; Hrast M; Mitrović A; Fonovič UP; Németh K; Barreteau H; Roper DI; Horváti K; Ferenczy GG; Kos J; Ilaš J; Gobec S; Keserű GM
    Eur J Med Chem; 2018 Dec; 160():94-107. PubMed ID: 30321804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent Warheads Targeting Cysteine Residue: The Promising Approach in Drug Development.
    Huang F; Han X; Xiao X; Zhou J
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36431829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Versatile Bioconjugation Chemistries of ortho-Boronyl Aryl Ketones and Aldehydes.
    Cambray S; Gao J
    Acc Chem Res; 2018 Sep; 51(9):2198-2206. PubMed ID: 30110146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Tractable Cysteines for Covalent Targeting by Screening Covalent Fragments.
    Petri L; Ábrányi-Balogh P; Tímea I; Pálfy G; Perczel A; Knez D; Hrast M; Gobec M; Sosič I; Nyíri K; Vértessy BG; Jänsch N; Desczyk C; Meyer-Almes FJ; Ogris I; Golič Grdadolnik S; Iacovino LG; Binda C; Gobec S; Keserű GM
    Chembiochem; 2021 Feb; 22(4):743-753. PubMed ID: 33030752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced approaches of developing targeted covalent drugs.
    Gai C; Harnor SJ; Zhang S; Cano C; Zhuang C; Zhao Q
    RSC Med Chem; 2022 Dec; 13(12):1460-1475. PubMed ID: 36561076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arylfluorosulfate-Based Electrophiles for Covalent Protein Labeling: A New Addition to the Arsenal.
    Martín-Gago P; Olsen CA
    Angew Chem Int Ed Engl; 2019 Jan; 58(4):957-966. PubMed ID: 30024079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-based covalent ligand discovery.
    Lu W; Kostic M; Zhang T; Che J; Patricelli MP; Jones LH; Chouchani ET; Gray NS
    RSC Chem Biol; 2021 Apr; 2(2):354-367. PubMed ID: 34458789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covalent fragment libraries in drug discovery-Design, synthesis, and screening methods.
    Hocking B; Armstrong A; Mann DJ
    Prog Med Chem; 2023; 62():105-146. PubMed ID: 37981350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.
    Hillebrand L; Liang XJ; Serafim RAM; Gehringer M
    J Med Chem; 2024 May; 67(10):7668-7758. PubMed ID: 38711345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteome-wide structural analysis identifies warhead- and coverage-specific biases in cysteine-focused chemoproteomics.
    White MEH; Gil J; Tate EW
    Cell Chem Biol; 2023 Jul; 30(7):828-838.e4. PubMed ID: 37451266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches.
    Zhang Y; Zhang D; Tian H; Jiao Y; Shi Z; Ran T; Liu H; Lu S; Xu A; Qiao X; Pan J; Yin L; Zhou W; Lu T; Chen Y
    Mol Pharm; 2016 Sep; 13(9):3106-18. PubMed ID: 27483186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROTACting the kinome with covalent warheads.
    Chatterjee DR; Kapoor S; Jain M; Das R; Chowdhury MG; Shard A
    Drug Discov Today; 2023 Jan; 28(1):103417. PubMed ID: 36306996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Covalent Targeting of Pyruvate Kinase M2 Using Arsenous Warheads.
    Wang J; Zhou S; Cheng Y; Cheng L; Qin Y; Zhang Z; Bi A; Xiang H; He X; Tian X; Liu W; Zhang J; Peng C; Zhu Z; Huang M; Li Y; Zhuang G; Tan L
    J Med Chem; 2023 Feb; 66(4):2608-2621. PubMed ID: 36723914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in covalent warheads for in vivo targeting of endogenous proteins.
    Shindo N; Ojida A
    Bioorg Med Chem; 2021 Oct; 47():116386. PubMed ID: 34509863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleophilic covalent ligand discovery for the cysteine redoxome.
    Fu L; Jung Y; Tian C; Ferreira RB; Cheng R; He F; Yang J; Carroll KS
    Nat Chem Biol; 2023 Nov; 19(11):1309-1319. PubMed ID: 37248412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors.
    McAulay K; Hoyt EA; Thomas M; Schimpl M; Bodnarchuk MS; Lewis HJ; Barratt D; Bhavsar D; Robinson DM; Deery MJ; Ogg DJ; Bernardes GJL; Ward RA; Waring MJ; Kettle JG
    J Am Chem Soc; 2020 Jun; 142(23):10358-10372. PubMed ID: 32412754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.